Business Wire

The I4MS Initiative Launches the First Disruptor Awards Contest for the Best Experiments Featuring Digital Transformation

Del

The European Commission’s Initiative I4MS has created the Disruptors Awards contest, a competition that aims to award the most innovative experiments and best cases in additive manufacturing, CPS, IoT, robotics, HPC or laser technologies. The Disruptors Awards Call will select the best cases illustrating a company's ability to innovate and implement ICT technologies to meet its business needs, bring radical innovation to their sector and capacity of achieving national or international scale.

This Call is available to SMEs that have received technological and financial support from the Innovation Actions that are part of the I4MS initiative (Fortissimo, Cloudflow, CloudSMEs, LASHARE, INTEFIX, EuRoC, Appolo, ReconCell, BeinCPPS, Fortissimo2, HORSE, MIDIH, Cloudifacturing, L4MS and AMable) since its foundation.

The best proposal will win the following prize package:

  • A Plane ticket and the accommodation of 1 representative of the winning experiment to participate in the Disruptors Awards Ceremony
  • A specially designed offline and online visibility during the Mobile World Congress and 2 exhibition tickets (access to selected seminars and courses are included).
  • A free booth or space to showcase the experiment during the FIWARE Summit Fall 2018
  • A tailor-made workshop with Danish Technological Institute and MADE about technological and innovation support in the realization process of the winning project.
  • A ticket for the I4MS Bootcamp, where a small group of SMEs will receive a brief training on pitching, fundraising and tips to connect with corporates and private investors.

The winning project will be also awarded with the I4MS visibility package which includes the promotion of the experiment and the winning SMEs or midcap via the I4MS online community, website, social networks, blog and I4MS newsletter as the best digital transformation case.

All applications must be in English and submitted before the 5 th of September 2018 at 17:00 (CET). The results will be published in October 2018 at i4ms.eu.

More information on http://i4ms.eu/about/disruptor-awards

I4MS is funded under the Factories of Future Program and H2020, and coordinated by Mobile World Capital Barcelona Foundation, FundingBox Accelerator, Foreningen MADE, Danish Technological Institute, FIWARE Foundation EV and Axencia Galega de Innovación.

Contact information

Silvia Valcarcel
Communication Executive of Mobile World Capital Barcelona
svalcarcel@mobileworldcapital.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

IONITY Fast Charging Network Relies on has·to·be Know-How for the Long Term24.4.2019 10:18:00 CESTPressemelding

The IONITY joint venture aims to help electromobility achieve a breakthrough in Europe with a nationwide network of super-fast charging stations. The Austrian electromobility provider, has·to·be, is playing an important role in this. The red-white-red company will take care of the reliable and trouble-free operation of the charging stations. The two companies have agreed on a long-term cooperation so that the expansion of the Europe-wide network can proceed according to plan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005465/en/ has·to·be and IONITY focus on long-term cooperation (Graphic: Business Wire) has·to·be, based in Radstadt (Salzburg), specializes in smart solutions for e-charging stations. For this purpose, the company has developed intelligent software for the management of electrical charging infrastructures. The product is called be.ENERGISED and is used successfully at more than 14,000 charging statio

Knopp Biosciences Receives FDA Orphan Drug Designation for Dexpramipexole for Treatment of Hypereosinophilic Syndrome24.4.2019 10:00:00 CESTPressemelding

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with high unmet needs, announced today that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to dexpramipexole, its oral drug candidate for the treatment of hypereosinophilic syndrome (HES). HES is a rare and often incapacitating disorder with limited treatment options. The FDA Orphan Drug Designation program provides a special status to drugs and biologics intended to treat, diagnose, or prevent diseases and disorders that affect fewer than 200,000 people in the U.S. This designation provides for a seven-year marketing exclusivity period against competition, as well as certain incentives, including federal grants, tax credits and a waiver of PDUFA filing fees. “We are very pleased to receive orphan drug designation for dexpramipexole for HES,” said Michael Bozik, M.D., CEO of Knopp Biosc

Enterprise Integration Middleware Leader, Fiorano Software, Announces Release of Fiorano Platform 12.024.4.2019 09:00:00 CESTPressemelding

Fiorano Software, a leader in Integration Middleware, API Management and peer-to-peer distributed systems, announced today the release of version 12.0 of the Fiorano ESB and API Management platform. The latest release with new adapters and tools includes enhanced and optimised features to improve performance of its servers delivering a more productive SOA and API Management deployment with a significant incremental return on investment. The platform offers a unified profile to run all Fiorano Servers in a single process and ships with several new adapters including a Kafka Connector, DynamoDB, AS4Connector, SMPPSend and WebSockets. Users can now import Event Processes directly from the Dashboard and optimize CRC processes by fetching components from local repositories. The new platform provides a new HTML5 dashboard, monetisation and security policies like JWT/JWS for API Management while supporting Open API specifications, OpenId Connect and time-based accessing and quota policies alo

Aptorum Group’s Smart Pharma announces launch of its asset backed Smart Pharma token (SMPT), supported by its computational repurposed drug discovery platform Smart-ACT™24.4.2019 08:30:00 CESTPressemelding

Aptorum Group Limited (Nasdaq:APM) is excited to announce the launch and issuance of its asset backed Smart Pharma Token (“SMPT”) by its wholly owned subsidiary group, Smart Pharma group and Smart Pharmaceutical Limited Partnership (“SPLP”) targeted in May 2019. SPLP is extremely pleased to have jointly developed the SMPT token with Aenco, an affiliated blockchain development company focused on applications in the healthcare and financial sector. The SMPT token, an ERC-1404 security compliant token, is a unique token that tokenizes valuable pharmaceutical drugs and their underlying intellectual property and associated allocation of cash flows induced by continual product development and commercialization. It is the intention of the Smart Pharma group to continue to incorporate Aenco’s blockchain technology into its pharmaceutical development and commercialization processes. Relying on intellectual property derived from the Smart-ACT™ platform, Smart Pharma’s in-house new and repurposed

Aptorum Group Establishes Smart Pharma to Focus on Computational Repurposed Drug Discovery for Orphan and Unmet Diseases24.4.2019 08:30:00 CESTPressemelding

Aptorum Group Limited (Nasdaq: APM) today announced the establishment of a new subsidiary group, Smart Pharma (“SmartP”), which operates its novel computational repurposed drug discovery, modeling and validation platform, together referred to as the “Smart-ACTTM” platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005095/en/ (Photo: Business Wire) Smart-ACTTM stands for Accelerated Commercialization of Therapeutics and encompasses state-of-the-art technology in systematic screening of existing approved drug molecules against selected therapeutic targets. Specifically, the Smart-ACTTM platform comprises of a network of modules and processes that simulate the effectiveness of drug molecules against diseases for outcome prediction and selection. The Smart-ACTTM platform will initially focus on the screening drug molecules for orphan diseases or unmet medical needs. To date, SmartP has, under the recently established

Aptorum Group Limited Announces Repurchase of USD13,500,000 Outstanding Convertible Bonds Due 201924.4.2019 08:15:00 CESTPressemelding

Aptorum Group Limited (NASDAQ: APM) (“Aptorum” or the “Company”), a pharmaceutical company focused on the development and commercialization of therapeutic and diagnostic technologies to tackle unmet medical needs, announced today that the Company, in a privately-negotiated transaction, repurchased all outstanding US$13,500,000 in aggregate principal amount of the 8.00 per cent. convertible bonds due 2019 (“Convertible Bonds”) from Peace Range Limited, a wholly owned subsidiary of Adamas Ping An Opportunities Fund LP, together with certain subscription right to subscribe up to the principal amount of the Bond at a US$12.17 (subject to adjustment) on or before December 17, 2019 (“Subscription Right”). The total consideration of the repurchase of the Convertible Bonds and the Subscription Right was US$13.6 million in cash, excluding accrued interest. The repurchase of the Convertible Bonds and Subscription Right was executed by Aptorum Investment Holding Limited, a wholly owned subsidiary